Cash cost of the wait: management is funding a defined waiting period whose end is already scheduled
The model's full reasoning — Q4 2021 call → NOWe need to determine if management describes the company as currently living through a defined waiting period it is paying for out of its own pocket, with a specific near-dated event ending the wait. The transcript mentions several initiatives: HRD solution, CarePath, DEEP-Lung-IV study, partnerships, etc. But does management describe a current cost with no benefit yet, and a specific near-dated event? Let's examine. Key points: They have launched HRD solution, have partnerships, are building capabilities. They mention CarePath and DEEP-Lung-IV study. They say "we are building capabilities" and "we are in a stage where we are demonstrating the value" - but is there a defined waiting period with costs? They mention "we are developing everything under design control" and "we don't intend to sell this CarePath DEEP-Lung-related capabilities before the end of the study." The study is ongoing, with 16 sites, and they will present results at ASCO. But is the company paying for this out of pocket? They are funding the study, but is it described as a cost with no benefit yet? They are investing in R&D, but that's normal operating expense. The question asks for a specific phenomenon: a company bearing the cost of a gap it has chosen to stand in, with the far edge dated and largely paid for. Management does not explicitly say "we are paying now for something not yet earning" in a way that matches. They talk about investments in growth, but not a defined waiting period with a specific near-dated event that will change earnings. They mention "we expect to unveil several exciting new products later this year" and "we will provide an update on preliminary findings at ASCO" - but that's not necessarily a crossing that changes earning capability. Also, they have existing revenue from platform, so they are already earning. The costs are ordinary operating expenses. There is no indication of a self-funded interval before a specific arrival that is the main current work. They are growing, but not in a waiting period. So answer NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| LILA | Liberty Latin America Ltd. | Q4 2023 | 2024-02-23 | C |
| SBS | Companhia de Saneamento Básico do Estado | Q3 2023 | 2023-11-10 | C+ |
| QTRX | Quanterix Corporation | Q3 2023 | 2023-11-07 | B |
| APPS | Digital Turbine, Inc. | Q1 2024 | 2023-08-08 | D |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| CDE | Coeur Mining, Inc. | Q1 2023 | 2023-05-11 | C+ |
| SOL | ReneSola Ltd | Q3 2022 | 2022-12-01 | C+ |
| FLL | Full House Resorts, Inc. | Q3 2022 | 2022-11-07 | B |
| EHTH | eHealth, Inc. | Q2 2021 | 2021-07-29 | F |
| IRT | Independence Realty Trust, Inc. | Q2 2018 | 2018-08-02 | B |
| YUM | Yum! Brands, Inc. | Q2 2018 | 2018-08-02 | C |
| IBTX | Independent Bank Group, Inc. | Q3 2017 | 2017-10-24 | A |
| FLEX | Flex Ltd. | Q1 2018 | 2017-07-28 | F |
| DAN | Dana Incorporated | Q1 2017 | 2017-05-02 | B |
SBS · Q3 2023 → YESThe question is whether management describes the company as currently living through a defined waiting period it's paying for out of its own pocket. YES The transcript shows management describing the company as currently bearing real, ongoing cash costs (salaries, consulting, transition work) for the IDP/restructuring program whose benefits (full expense reduction, shared-services center operational) are not yet realized. The far side is a specific, near-dated event: full 3.7% staff reduction and shared-services center operational by mid-2024 (July 2024 for full benefit), with the program already in motion and on schedule. Management frames this as the main current work, not a setback, and treats the costs as self-funded. This meets all three conditions.
EHTH · Q2 2021 → YESThe question is whether management describes the company as currently living through a defined waiting period it is paying for out of its own pocket. YES The transcript shows management describing the company as currently living through a defined waiting period for the AEP, paying for it out of its own pocket through heavy investments in internal agents and quality initiatives. They hired agents early, many still in training with lower productivity, and are bearing the cost of additional training and customer service expansion in Q3. This is framed as a chosen investment to improve enrollment quality and prepare for the fourth-quarter AEP, not an apology or external issue.
YUM · Q2 2018 → YESThe question is whether management describes the company as currently living through a defined waiting period it is paying for out of its own pocket. YES The transcript shows management describing a clear, self-funded transition cost tied to the refranchising effort. They explicitly call out the “timing mismatch between G&A savings and refranchising” as one of the four items weighing on Q2 core operating profit, and they quantify the full-year headwind at 6 7 percentage points. This is presented as a real, ongoing drag on current results while they complete the shift to 98 % franchised by year-end 2018 and reach the 1.7 % G&A run-rate target in 2019.